| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Human GPR43 (FFAR2). BTI-A-404 is a selective and competitive inverse agonist of human GPR43.
|
|---|---|
| ln Vitro |
In vitro, BTI-A-404 acts as a potent, selective, and competitive inverse agonist at human GPR43. The compound shows selectivity for GPR43 over other related receptors. It is used to study the role of GPR43 in metabolic and inflammatory pathways. Detailed IC₅₀ values and functional assay data are available in the primary literature.
|
| ln Vivo |
In vivo, BTI-A-404 can be used for research on inflammation, obesity, and type 2 diabetes. The compound has been evaluated in animal models of these conditions to elucidate the role of GPR43 signaling. Further details on in vivo efficacy are available in the primary research literature.
|
| Enzyme Assay |
Non-cell receptor binding assays are performed using membrane preparations from cells expressing human GPR43. Radioligand binding studies are conducted using a suitable labeled ligand for FFAR2. Membranes are incubated with the radioligand and varying concentrations of BTI-A-404 (0.001-100 μM). Nonspecific binding is determined with excess unlabeled ligand. After incubation at 25°C for 60-120 minutes, filtration and scintillation counting are performed. Ki values are calculated from competition curves. Alternatively, GTPγS binding assays are used to assess inverse agonist activity.
|
| Cell Assay |
Cellular functional assays are performed using cells expressing human GPR43 (e.g., CHO or HEK-293 cells). Inverse agonist activity is measured by monitoring constitutive GPR43 activity, such as basal GTPγS binding or downstream signaling (e.g., cAMP or ERK phosphorylation). Cells are treated with BTI-A-404 at concentrations ranging from 0.01 nM to 100 μM. Signal inhibition is measured, and IC₅₀ values are calculated from dose-response curves.
|
| Animal Protocol |
In vivo studies are conducted in rodent models of metabolic and inflammatory diseases. BTI-A-404 is administered via intraperitoneal or oral routes at doses determined from pharmacokinetic studies. Disease parameters including glucose tolerance, insulin sensitivity, inflammatory cytokine levels, and body weight are assessed. Tissue samples are collected for target engagement and biomarker analysis.
|
| ADME/Pharmacokinetics |
Published pharmacokinetic data for BTI-A-404 are limited. As a small molecule inverse agonist, it is expected to have reasonable oral bioavailability and tissue distribution. Further studies are needed to determine half-life, clearance, metabolism, and protein binding. The compound is typically administered in research settings via intraperitoneal injection.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicology data for BTI-A-404 are not available in the public domain. No significant toxicity has been reported in published studies at effective doses. Standard safety pharmacology studies would be required for therapeutic development. The compound is generally well-tolerated in research settings at pharmacological doses.
|
| References | |
| Additional Infomation |
BTI-A-404 is a research tool for studying GPR43 (FFAR2) signaling in inflammation, obesity, and type 2 diabetes. GPR43 is a receptor for short-chain fatty acids and plays a role in metabolic regulation and immune function. As an inverse agonist, BTI-A-404 helps elucidate the constitutive activity of GPR43 and its physiological roles. The compound is not approved for clinical use and is available for research purposes only.
|
| Molecular Formula |
C22H26N4O2
|
|---|---|
| Molecular Weight |
378.47
|
| Exact Mass |
378.205
|
| CAS # |
537679-57-5
|
| PubChem CID |
2952084
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.8
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
612
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC(=CC(=C1)NC(=O)C2=C(NC(=O)NC2C3=CC=C(C=C3)N(C)C)C)C
|
| InChi Key |
JQVNMIXFWKEYQJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H26N4O2/c1-13-10-14(2)12-17(11-13)24-21(27)19-15(3)23-22(28)25-20(19)16-6-8-18(9-7-16)26(4)5/h6-12,20H,1-5H3,(H,24,27)(H2,23,25,28)
|
| Chemical Name |
4-[4-(dimethylamino)phenyl]-N-(3,5-dimethylphenyl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6422 mL | 13.2111 mL | 26.4222 mL | |
| 5 mM | 0.5284 mL | 2.6422 mL | 5.2844 mL | |
| 10 mM | 0.2642 mL | 1.3211 mL | 2.6422 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
